πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11845937

RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845931

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845808

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845787

DNA antibody constructs for use against HIV

Inovio Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845778

Prefusion PIV F immunogens and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845752

Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B

Aligos Therapeutics, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845747

Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845727

Aldehyde and ketone derivatives of psilocybin and methods of using

Enveric Biosciences Canada Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11845726

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844867

Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug

Rani Therapeutics, LLC Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844857

Treating gynecological malignancies with deployable implants

Covidien LP Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844843

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844841

Dosing regimens and related compositions and methods

Apellis Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844816

Compositions and methods for augmenting the nasal microbiome

Arizona Board of Regents on Behalf of Northern Arizona University Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844805

Formulations of testosterone and methods of treatment therewith

The Board of Regents of the University of Texas System Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844801

Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

Aclaris Therapeutics, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844799

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting r

Actinium Phamaceuticals, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844779

PKC-Delta-I inhibitor formulations and uses thereof

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844830

Vaccines for human papilloma virus and methods for using the same

Inovio Pharmaceuticals, Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844771

Methods of treating acute respiratory distress syndrome using colchicine

INSTITUT DE CARDIOLOGIE DE MONTREAL Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844769

Use of cysteamine and derivatives thereof to suppress tumor metastases

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844765

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844764

Agitation process for preparing a carbetocin drug product

ACADIA Pharmaceuticals Inc. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11844773

Solid solution compositions and use in chronic inflammation

Infirst Healthcare Limited Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted